Neuroprotective effect of bromelain in 6-hydroxydopamine induced in vitro model of Parkinson’s disease

ArticleAçık Erişim

Özet

Background: This study was designed to investigate the neuroprotective effects of bromelain, which is known to have anti-oxidant and anti-inflammatory properties, against the neurotoxicity (induced by 6-OHDA) in SH-SY5Y cells. Methods and results: To establish Parkinson’s Disease (PD) model in cell culture conditions, SH-SY5Y cells were exposed to 200 µM 6-OHDA for 1 day. Prior to 6-OHDA treatment, SH-SY5Y cells had been pre-treated with bromelain (25 µg/mL, 50 µg/mL, 75 µg/mL and 100 µg/mL). After 1 day, cell viability was determined with the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) and lactate dehydrogenase (LDH) assays. Oxidative stress was assessed with total antioxidant capacity (TAC), total oxidant status (TOS), glutathione reductase (GR) and malondialdehyde (MDA) analyses. The effect of the bromelain in SH-SY5Ycells was also examined by 4′,6-diamidino-2-phenylindole (DAPI) staining. We found that 6-OHDA increased LDH leakage, and cellular apoptosis in SH-SY5Y cells. 6-OHDA aggravated oxidative stress by increasing TOS, MDA and GR and eventually promoted apoptosis in SH-SY5Y cells, while pretreatment with bromelain attenuated these toxic effects of 6-OHDA. Conclusions: These findings indicated that bromelain, with its neuroprotective features can be useful for neuroprotection in PD. © 2021, The Author(s), under exclusive licence to Springer Nature B.V.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13428Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1007/s11033-021-06779-yYayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorFerah Okkay, Irmak
dc.contributor.authorOkkay, Ufuk
dc.contributor.authorCicek, Betul
dc.contributor.authorYilmaz, Aysegul
dc.contributor.authorYesilyurt, Fatma
dc.contributor.authorMendil, Ali Sefa
dc.contributor.authorHacimuftuoglu, Ahmet
dc.date.accessioned2026-10-18T20:28:15.528122488Z
dc.date.available2026-10-18T20:28:15.528122488Z
dc.date.issued2021
dc.description.abstractBackground: This study was designed to investigate the neuroprotective effects of bromelain, which is known to have anti-oxidant and anti-inflammatory properties, against the neurotoxicity (induced by 6-OHDA) in SH-SY5Y cells. Methods and results: To establish Parkinson’s Disease (PD) model in cell culture conditions, SH-SY5Y cells were exposed to 200 µM 6-OHDA for 1 day. Prior to 6-OHDA treatment, SH-SY5Y cells had been pre-treated with bromelain (25 µg/mL, 50 µg/mL, 75 µg/mL and 100 µg/mL). After 1 day, cell viability was determined with the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) and lactate dehydrogenase (LDH) assays. Oxidative stress was assessed with total antioxidant capacity (TAC), total oxidant status (TOS), glutathione reductase (GR) and malondialdehyde (MDA) analyses. The effect of the bromelain in SH-SY5Ycells was also examined by 4′,6-diamidino-2-phenylindole (DAPI) staining. We found that 6-OHDA increased LDH leakage, and cellular apoptosis in SH-SY5Y cells. 6-OHDA aggravated oxidative stress by increasing TOS, MDA and GR and eventually promoted apoptosis in SH-SY5Y cells, while pretreatment with bromelain attenuated these toxic effects of 6-OHDA. Conclusions: These findings indicated that bromelain, with its neuroprotective features can be useful for neuroprotection in PD. © 2021, The Author(s), under exclusive licence to Springer Nature B.V.
dc.identifier.doi10.1007/s11033-021-06779-y
dc.identifier.eissn1573-4978
dc.identifier.endpage7717
dc.identifier.issn0301-4851
dc.identifier.issue12
dc.identifier.pmid34643923
dc.identifier.scopus2-s2.0-85116919353
dc.identifier.startpage7711
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13428
dc.identifier.volume48
dc.identifier.wosWOS:000706928900003
dc.language.isoen
dc.publisherSpringer Science and Business Media B.V.
dc.relation.ispartofMolecular Biology Reports
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subject6-OHDA
dc.subjectBromelain
dc.subjectNeuroprotection
dc.subjectParkinson’s disease
dc.subjectSH-SY5Y cell
dc.subjectAnti-Inflammatory Agents
dc.subjectAntioxidants
dc.subjectApoptosis
dc.subjectBromelains
dc.subjectCell Line, Tumor
dc.subjectCell Survival
dc.subjectHumans
dc.subjectNeurons
dc.subjectNeuroprotective Agents
dc.subjectOxidative Stress
dc.subjectOxidopamine
dc.subjectParkinson Disease
dc.subjectReactive Oxygen Species
dc.subjectglutathione reductase
dc.subjectmalonaldehyde
dc.subjectantiinflammatory agent
dc.subjectantioxidant
dc.subjectneuroprotective agent
dc.subjectreactive oxygen metabolite
dc.subjectantiinflammatory activity
dc.subjectantioxidant activity
dc.subjectArticle
dc.subjectcell culture
dc.subjectcell viability
dc.subjectcontrolled study
dc.titleNeuroprotective effect of bromelain in 6-hydroxydopamine induced in vitro model of Parkinson’s disease
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus30
rdl.citation.wos28
rdl.departmentDepartment of Physiology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)